Table 1.
Baseline characteristics of the modified intention-to-treat population
| Variable | CA-SAP group (n = 51) | SAP group (n = 53) |
|---|---|---|
| Age, years | 63 (57–68) | 63 (56–68) |
| Sex | ||
| Male | 42 (82.4) | 35 (66.0) |
| Female | 9 (17.6) | 18 (34.0) |
| ECOG performance status | ||
| 0 | 33 (64.7) | 36 (67.9) |
| 1 | 18 (35.3) | 17 (32.1) |
| Lauren classification | ||
| Intestinal | 11 (21.6) | 10 (18.9) |
| Diffuse | 39 (76.5) | 42 (79.2) |
| Unknown | 1 (2.0) | 1 (1.9) |
| Tumor location | ||
| Upper 1/3 | 22 (43.1) | 29 (54.7) |
| Middle 1/3 | 10 (19.6) | 6 (11.3) |
| Lower 1/3 | 11 (21.6) | 11 (20.8) |
| Mixed | 8 (15.7) | 7 (13.2) |
| Tumor size, mm | 65 (45–80) | 60 (50–75) |
| Borrmann type | ||
| II-III | 43 (84.3) | 48 (90.6) |
| IV | 8 (15.7) | 5 (9.4) |
| cT stage | ||
| T3 | 5 (9.8) | 8 (15.1) |
| T4 | 46 (90.2) | 45 (84.9) |
| PD-L1 expression (CPS) | ||
| <1 | 23 (45.1) | 23 (43.4) |
| ≥1 | 27 (52.9) | 28 (52.8) |
| Unknown | 1 (2.0) | 2 (3.8) |
| MSI status | ||
| MSS | 47 (92.2) | 48 (90.6) |
| MSI-High | 3 (5.9) | 3 (5.7) |
| Unknown | 1 (2.0) | 2 (3.8) |
Data are No. (%) or median (first quartile-third quartile [Q1–Q3]). Because of rounding, not all percentages add up to 100%.
CA-SAP camrelizumab, apatinib, nab-paclitaxel, and S-1, SAP nab-paclitaxel and S-1, ECOG Eastern Cooperative Oncology Group, PD-L1 programmed death-ligand 1, CPS combined positive score, MSI microsatellite instability, MSS microsatellite stable.